Drug intelligence / Profile preview

SBRX20

Development stage: Preclinical
Lead developer: Stramsen Biotech

Overview

SBRX20 is a plant-based drug candidate being developed by Stramsen Biotech, Inc. It is part of the company's SBRX series of botanical therapeutics. The candidate is designed to target a wide spectrum of viral infections, including Hepatitis A, B, C, D, E, and G, as well as yellow fever and various viral fevers. While the drug is listed in the company's active pipeline, detailed information regarding its specific molecular mechanism, pharmacological targets, and current clinical trial phase is not publicly available.

Beyond the preview

Go deeper on SBRX20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBRX20.

Explore the full profile